Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingbo Wang

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.
Frontiers in Immunology|January 8, 2026
Xuebijing injection mitigates instant blood-mediated inflammatory reaction and enhances intrahepatic islet transplantation via target NF-κB pathwayYixiang Zhan, Yingbo Wang, Boya Zhang, et al.
Cell Transplantation|September 16, 2025
A microporous liraglutide-releasing silk fibroin scaffold improves islet transplantation outcomes through anti-inflammatory effectYixiang Zhan, Xinchen Du, Yan Li, et al.
Cancer Medicine|December 18, 2021
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO studySara Pizzamiglio, Giulia Cosentino, Chiara M Ciniselli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical TrialDavid Venet, Mattia Rediti, Marion Maetens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast CancerIoannis A Vathiotis, Myrto K Moutafi, Prajan Divakar, et al.
The New England Journal of Medicine|December 12, 2019
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast CancerDennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.
Frontiers in Immunology|January 8, 2026
Xuebijing injection mitigates instant blood-mediated inflammatory reaction and enhances intrahepatic islet transplantation via target NF-κB pathwayYixiang Zhan, Yingbo Wang, Boya Zhang, et al.
Cell Transplantation|September 16, 2025
A microporous liraglutide-releasing silk fibroin scaffold improves islet transplantation outcomes through anti-inflammatory effectYixiang Zhan, Xinchen Du, Yan Li, et al.
Cancer Medicine|December 18, 2021
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO studySara Pizzamiglio, Giulia Cosentino, Chiara M Ciniselli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical TrialDavid Venet, Mattia Rediti, Marion Maetens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast CancerIoannis A Vathiotis, Myrto K Moutafi, Prajan Divakar, et al.
The New England Journal of Medicine|December 12, 2019
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast CancerDennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
Pageof 9